In contrast, both genotypic and allelic frequencies of p53 codon 72 polymorphism were significantly different between the bladder cancer cohort 2 and the non-cancerous controls (genotype, P=0.017; allele, P=0.014), in which the genotype Pro/Pro and Pro allele was more frequent in patients than in controls (genotype Pro/Pro, 24.47 vs. 18.31%; C allele, 53.72 vs. 42.25%). The gene discussed is TP53; the disease is urinary bladder cancer.